Effects of low or medium-dose of prednisone on insulin resistance in patients with systemic Lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 28, Issue 4, 2010, Pages 483-489

  Sabio, J M ^a   Vargas Hitos, J A ^a   Navarrete, N ^a   Hidalgo Tenorio, C ^a   Jimenez Alonso J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Atherosclerosis; Corticosteroids; Insulin; Insulin resistance; Metabolic syndrome; Prdnisone; Systemic lupus erythematosus

Indexed keywords

GLUCOCORTICOID; INSULIN; PREDNISONE;

ADULT; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDNISONE; RISK FACTORS; TREATMENT OUTCOME;

EID: 79952053785     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. AVALOS I, RHO YH, CHUNG CP, STEIN CM Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26 (Suppl. 51): S5-13.
2. GRUNDY SM, CLEEMAN JI, DANIELS SR et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
3. EL MAGADMI M, AHMAD Y, TURKIE W et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006; 33: 50-6.
4. CHUNG CP, AVALOS I, OESER A et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208-14.
5. BULTINK IE, TURKSTRA F, DIAMANT M, DIJKMANS BA, VOSKUYL AE Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26: 32-8.
6. SABIO JM, ZAMORA-PASADAS M, JIMÉNEZJÁIMEZ J et al. Metabolic syndrome in systemic lupus erythematosus from Southern Spain. Lupus 2008; 17: 849-59.
7. SABIO JM, VARGAS-HITOS J, ZAMORAPASADAS M et al. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 2009; 36: 2204-11
8. BONORA E, KIECHL S, WILLEIT J et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care 2007; 30: 318-24.
9. POSADAS-ROMERO C, TORRES-TAMAYO M, ZAMORA-GONZÁLEZ J et al. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 160-5.
10. ROMAN MJ, SHANKER BA, LOCKSHIN DA et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
11. PETRI M, LAKATTA C, MAGDER L, GOLDMAN D Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus. Am J Med 1994; 96: 254-9.
12. KARP I, ABRAHAMOWICZ M, FORTIN PR et al. Recent corticosteroids use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus. Arthritis Rheum 2008; 59: 169-75.
13. ZARKOVIC M, BELESLIN B, CIRIC J et al. Glucocorticoid effect on insulin sensitivity: a time frame. J Endocrinol Invest 2008; 31: 238-42.
14. ALBERTI KG, ZIMMET PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
15. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
16. GLADMAN D, GINZLER E, GOLDSMITH C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9.
17. CHUNG CP, OESER A, SOLUS JF et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58: 2105-12.
18. BAXTER JD, FORSHAM PH Tissue effects of glucocorticoids. Am J Med 1972; 53: 573-89.
19. GRUNDY SM Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004: 89: 2595-600.
20. OESER A, CHUNG CP, ASANUMA Y, AVALOS I, STEIN M Obesity is an independent contributor to functional capacity and inflammation in systemic lupus rythematosus. Arthritis Rheum 2005; 52: 3651-9.
21. PARK K, STEFFES M, LEE DH, HIMES JH, JACOBS DR JR Association of inflammation with worsening HOMA-insulin resistance. Diabetologia 2009; 52: 2337-44.
22. DEEPA R, VELMURUGAN K, ARVIND K et al. Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance: the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 2006; 55: 1232-8.
23. BEVAN AP, KROOK A, TIKERPAE J, SEABRIGHT PJ, SIDDLE K, SMITH GD Chloroquine extends the lifetime of the actived insulin receptor complex in endosomes. J Biol Chem 1997; 272: 26833-40.
24. ARCARO G, CRETTI A, BALZANO S et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105: 576-82.
25. LIDAR M, BRAF A, GIVOL N et al. Antiinsulin antibodies and the natural autoimmune response in systemic lupus erythematosus. Lupus 2001, 10: 81-6.
26. WEI L, MACDONALD TM, WALKER BR Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-70.